• Species Reactivity

  Human, Mouse

• Specificity

  Detects multiple isoforms of human and mouse APP phosphorylated at sites corresponding to T668 of the human APP695 isoform.

• Source

  Monoclonal Mouse IgG    ₁ Clone # 304904

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Phosphopeptide containing human APP T668 site

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 µg/mL

  See below

• 
  

• Immunohistochemistry

  8-25 µg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: APP

Amyloid precursor protein (APP) is a type I membrane protein with several human isoforms due to alternative splicing. APP-770, -751, and -733 contain a Kunitz protease inhibitor (KPI) domain (residue 291 - 342) and APP-695 does not. APP is a cell surface molecule with many functions. It can be processed proteolytically in two different pathways. In one pathway, beta - and gamma -secretase cleave at the  beta  site between residue 670 and 671 and the gamma site between residue 711 and 714 to produce beta ‑amyloid peptide (A beta 40 and A beta 42), a major component in plaques found in brains of patients with Alzheimer's disease (1). The other pathway involves alpha -secretase that cleaves residues between 687 and 688. It is antiamyloidogenic due to its benign character and the prevention of the A beta peptide formation (2). Soluble APP containing the KPI domain, also referred to as protease nexin II, is a potent inhibitor of serine proteases and may have additional functions. For example, it may regulate the contact face of blood coagulation and limit thrombosis specially in brain due to its localization and coagulation factor XI inhibiting activity (3, 4).

• References:

1. Haass, C. (2004) EMBO J. 23:483.

2. Lichtenthaler, S. F. and C. Haass (2004) J. Clin. Invest. 113:1384.

3. Badellino, K.O. and P.N. Walsh (2000) Biochemistry 39:4769.

4. Xu, F. et al. (2005) Proc. Natl. Acad. Sci USA. 102:18135.

• Long Name:

  Amyloid Precursor Protein

• Entrez Gene IDs:

  351 (Human); 11820 (Mouse)

• Alternate Names:

  amyloid beta (A4) precursor protein-binding, family B, member 2; amyloid beta A4 precursor protein-binding family B member 2; Amyloid beta precursor protein; Amyloid beta; APP; Protease Nexin II